Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK C481S |
| Therapy | NX-5948 |
| Indication/Tumor Type | diffuse large B-cell lymphoma activated B-cell type |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481S | diffuse large B-cell lymphoma activated B-cell type | predicted - sensitive | NX-5948 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, NX-5948 treatment resulted in degradation of BTK C481S and inhibited proliferation of an activated B-cell type diffuse large B-cell lymphoma (ABC-DLBCL) cell line harboring BTK C481S in culture and inhibited tumor growth in a cell line xenograft model (Blood 2021 138 (Supp 1):2251). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies | Full reference... |